

PERSONNAL INFORMATIONS

NAME	ELEFSINOTIS
SURNAME	IOANNIS
DEGREE	ASSISTANT PROFESSOR
SECTOR	MEDICINE-NURSING
LABORATORY/CLINIC/INSTITUTE	INTERNAL MEDICINE/UNIVERSITY OF ATHENS
TEL. Nr	0030-210-7461497
FAX	0030-210-7461497
E-MAIL	ielefs@nurs.uoa.gr
OFFICE/BUILDING	NURSING SCHOOL, ATHENS UNIVERSITY
WORK ADDRESS	Papadiamantopoulou 123/Goudi, Athens

COURSES

UNDERGRADUATE	
1	MEDICAL DEPARTMENT, SCHOOL OF HEALTH SCIENCES, UNIVERSITY OF PATRAS
POST-GRADUATE	
1	DEPARTMENT OF INTERNAL MEDICINE, HIPPOKRATON HOSPITAL OF ATHENS, GREECE
2	DEPARTMENT OF INTERNAL MEDICINE-HEPATOTOLOGY, VALL DE HEBRON UNIVERSITY HOSPITAL, BARCELONA, SPAIN

STUDIES - ACADEMIC TITLES

Doctoral Degrees	2002 PhD- MEDICAL SCHOOL, UNIVERSITY OF ATHENS
-------------------------	--

ACADEMIC CAREER

Lecturer...	2006-2010
Assist. Professor	2010-today

RESEARCH INTERESTS

Epidemiology of viral hepatitis and infectious diseases
Viral hepatitis in special populations (pregnancy, elderly, drug users etc)
Vaccine preventable diseases
Liver diseases in pregnancy
Treatment of chronic viral hepatitis
Hepatocellular carcinoma

SELECTED SCIENTIFIC PUBLICATIONS

1. [Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection.](#)

Elefsiniotis IS, Tsoumacas K, Papadakis M, Vlachos G, Saroglou G, Antsaklis A.

Eur J Intern Med. 2011 Apr;22(2):182-6. Epub 2011 Jan 7.

2. [Presence of HBV-DNA in Cord Blood Is Associated with Spontaneous Preterm Birth in Pregnant Women with HBeAg-Negative Chronic Hepatitis B Virus Infection.](#)

Elefsiniotis IS, Papadakis M, Vlachos G, Vezali E, Tsoumacas K, Saroglou G, Antsaklis A.

Intervirology. 2011 Feb 12. [Epub ahead of print]

3. [Translation and validation of the Greek chronic liver disease questionnaire.](#)

Kollia Z, Patelarou E, Vivilaki V, Kollia E, Kefou F, Elefsiniotis I, Dourakis SP, Brokalaki H.

World J Gastroenterol. 2010 Dec 14;16(46):5838-44.

4. [Infection Probability Score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy.](#)

Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I.

Eur J Oncol Nurs. 2010 Dec 2. [Epub ahead of print]

5. [Spontaneous preterm birth in women with chronic hepatitis B virus infection.](#)

Elefsiniotis I, Tsoumacas K, Vezali E, Glynou I, Drakoulis N, Saroglou G.

Int J Gynaecol Obstet. 2010 Sep;110(3):241-4. Epub 2010 Jun 3.

6. [Current vaccination coverage against hepatitis B among pregnant women in Greece: far away from the ideal target.](#)

Elefsiniotis IS, Brokalaki H, Tsoumacas K, Vezali E, Glynou I, Saroglou G.

Eur J Obstet Gynecol Reprod Biol. 2010 Oct;152(2):227-8. Epub 2010 Jul 2. No abstract available.

7. [Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients.](#)

Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I.

BMC Infect Dis. 2010 May 26;10:135.

8. [Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic.](#)

Stamataki P, Papazafiropoulou A, Elefsiniotis I, Giannakopoulou M, Brokalaki H,

Apostolopoulou E, Sarafis P, Saroglou G.

BMC Infect Dis. 2010 Feb 15;10:27

9. [Hepatitis B markers and vaccination-induced protection rate among Albanian pregnant women in Greece.](#)

Elefsiniotis IS, Vezali E, Brokalaki H, Tsoumakas K.

World J Gastroenterol. 2009 Nov 21;15(43):5498-9.

10. [Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.](#)

Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R.

Eur J Intern Med. 2009 Sep;20(5):478-81.

11. [Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.](#)

Elefsiniotis IS, Vezali E, Mihas C, Saroglou G.

Intervirology. 2009;52(5):247-51. Epub 2009 Jul 14.

12. [Solitary internal jugular vein invasion by thyroid carcinoma: resection and reconstruction.](#)

Fotis T, Konstantinou E, Mariolis-Sapsakos T, Mitsos A, Restos S, Katsenis K, Elefsiniotis I, Kapellakis G.

J Vasc Nurs. 2009 Jun;27(2):46-7. Review.

13. [Clinical significance of hepatitis B surface antigen in cord blood of hepatitis B e-antigen-negative chronic hepatitis B virus-infected mothers.](#)

Elefsiniotis IS, Papadakis M, Vlahos G, Daskalakis G, Saroglou G, Antsaklis A.

Intervirology. 2009;52(3):132-4. Epub 2009 May 25.

14. [Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity.](#)

Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, Vezali E, Mihas C, Mariolis-Sapsakos T, Koutsounas S, Paraskevas E, Saroglou G.

J Viral Hepat. 2009 Oct;16(10):738-42. Epub 2009 Apr 22.

15. [Impact of hepatitis B exposure on sustained virological response rates of highly viremic chronic hepatitis C patients.](#)

Elefsiniotis IS, Pavlidis C, Vezali E, Mariolis-Sapsakos T, Koutsounas S, Saroglou G.

Gastroenterol Res Pract. 2009;2009:812140. Epub 2009 Apr 15.

16. [Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?](#)

Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G.

J Gastroenterol Hepatol. 2009 Jun;24(6):1024-9. Epub 2009 Mar 11.

17. [Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.](#)

Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.

J Med Virol. 2009 May;81(5):848-52.

18. [Surveillance for hepatitis B virus infection in pregnant women in Greece shows high rates of chronic infection among immigrants and low vaccination-induced protection rates: preliminary results of a single center study.](#)

Elefsiniotis IS, Glynnou I, Zorou I, Magaziotou I, Brokalaki H, Apostolopoulou E, Vezali E,

Kada H, Saroglou G.

Euro Surveill. 2009 Mar 5;14(9):5-7.

19. [Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?](#)

Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ.

Hepatology. 2008 Nov;48(5):1451-9.

20. [Large intestine histopathology of pegylated-interferon-alpha plus ribavirin treated chronic hepatitis C patients.](#)

Pantazis KD, Elefsiniotis IS, Papaioannou D, Brokalaki H, Bonatsos G, Mavrogianis C.

Gastroenterol Res Pract. 2008;2008:637517. No abstract available.

21. [New data concerning the epidemiology of Hepatitis B virus infection in Greece.](#)

Pantazis KD, Elefsiniotis IS, Brokalaki H.

Gastroenterol Res Pract. 2008;2008:580341.

22. [Atypical autoimmune polyglandular syndrome type 3 overlapped by chronic HCV infection resulting in carcinogenesis and fatal infection.](#)

Elefsiniotis IS, Papatsimpas G, Liatsos GD, Tasidou A, Moulakakis A.

South Med J. 2008 Jul;101(7):756-8.

23. [Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.](#)

Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD, Moulakakis A, Tsianos EV.

Eur J Intern Med. 2008 Jun;19(4):266-70. Epub 2008 Jan 15.

24. [Post-partum thyroiditis in women with chronic viral hepatitis.](#)

Elefsiniotis IS, Vezali E, Pantazis KD, Saroglou G.

J Clin Virol. 2008 Apr;41(4):318-9. Epub 2008 Feb 20. No abstract available.

25. [Maternal chronic hepatitis B virus does not affect neonatal biotinidase activity.](#)

Vlachos GD, Schulpis KH, Papakonstantinou E, Papadakis M, Elefsiniotis I, Papassotiriou I, Antsaklis A.

Acta Paediatr. 2008 Mar;97(3):362-5. Epub 2008 Jan 31.

26. [Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection.](#)

Elefsiniotis IS, Pantazis KD, Dimitroulopoulos D, Koutsounas S, Moulakakis A, Paraskevas E.

Indian J Gastroenterol. 2007 Sep-Oct;26(5):209-13.

27. [Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.](#)

Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Buti M.

J Viral Hepat. 2007 Dec;14(12):835-40.

28. [Case report: mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl.](#)

Elefsiniotis IS, Liatsos GD, Stamelakis D, Moulakakis A.

Environ Health Perspect. 2007 Oct;115(10):1479-81.

29. [Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos\(t\)ide analogues.](#)

Rodriguez-Frias F, Jardi R, Schaper M, Gimferrer M, Elefsiniotis I, Tabernero D, Esteban R, Buti M.

J Med Virol. 2007 Nov;79(11):1671-3.

30. [Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study.](#)

Elefsiniotis IS, Fotos NV, Pantazis KD, Papadeli D, Mavrogiannis C.

Hepatogastroenterology. 2007 Apr-May;54(75):2 p preceding table of contents. No abstract available.

31. [Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.](#)

Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.

J Hepatol. 2007 Sep;47(3):366-72. Epub 2007 May 24.

32. [Passive-active immunoprophylaxis for all infants born from HBeAG-negative chronic HBV-infected mothers: Is it a cost-effective strategy?](#)

Elefsiniotis IS, Papadakis MA, Vlahos G, Antsaklis A.

Hepatol Res. 2007 Jul;37(7):577-8. No abstract available.

33. [Unusual onset of varicella zoster reactivation with meningoencephalitis, followed by rhabdomyolysis and renal failure in a young, immunocompetent patient.](#)

Pirounaki M, Liatsos G, Elefsiniotis I, Skounakis M, Moulakakis A.

Scand J Infect Dis. 2007;39(1):90-3.

34. [Heparin-induced thrombocytopenia due to heparin flushes: report of two cases.](#)

Vezali E, Elefsiniotis I, Pirounaki M, Boltsis N, Paizis V, Moulakakis A.

Int J Clin Pract. 2007 Mar;61(3):516-8. No abstract available.

35. [Unusual initial presentation of primary systemic \(AL\) amyloidosis with severe cardiomyopathy and fatal outcome.](#)

Vezali E, Elefsiniotis I, Tsiofis C, Kallikazaros I.

Hellenic J Cardiol. 2006 Nov-Dec;47(6):381-5.

36. [Intrauterine-transplacental transmission of hepatitis B virus \(HBV\) from hepatitis B e antigen negative \(precore mutant, G1896A\) chronic HBV infected mothers to their infants. Preliminary results of a prospective study.](#)

Papadakis MA, Elefsiniotis IS, Vlahos G, Daskalakis G, Barbatis C, Antsaklis A.

J Clin Virol. 2007 Feb;38(2):181-3. Epub 2006 Dec 4. No abstract available.

37. [Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy.](#)

Elefsiniotis IS, Pantazis KD, Ketikoglou ID, Koutsounas SI, Tsianos EV.

Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1227-31.

38. [Serological and virological profile of chronic HBV infected women at reproductive age in Greece. A two-year single center study.](#)

Elefsiniotis IS, Glynou I, Brokalaki H, Magaziotou I, Pantazis KD, Fotiou A, Liosis G, Kada H, Saroglou G.

Eur J Obstet Gynecol Reprod Biol. 2007 Jun;132(2):200-3. Epub 2006 Oct 9.

39. [Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data.](#)

Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D, Ketikoglou I, Paraskevas E, Kanatakis S, Chrysagis D, Dalekos GN, Tzathas C, Protopapas A, Gigi E, Tsianos E, Kartalis G.

J Gastrointest Liver Dis. 2006 Sep;15(3):213-9.

40. [Seroepidemiological study of viral hepatitis among workers of the Cleaning Department of the Municipality of Vyronas: Preliminary results of a single centre study.](#)

Mariolis A, Mihas C, Magaziotou I, Alevizos A, Gizlis V, Papathanasiou M, Lentzas I, Konstantinou E, Elefsiniotis I.

Public Health. 2006 Nov;120(11):1088-9. Epub 2006 Sep 26. No abstract available.

41. [Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.](#)

Elefsiniotis IS, Petrocheilou A, Scarmeas N, Ketikoglou I, Pantazis KD, Toutouza M, Tsianos EV.

J Clin Virol. 2006 Dec;37(4):329-31. Epub 2006 Sep 25.

42. [Co-existing sarcoidosis and autoimmune pernicious anaemia: a rare combination.](#)

Pirounaki M, Liatsos G, Elefsiniotis I, Vezali E, Moulakakis A.

Int J Tuberc Lung Dis. 2006 Aug;10(8):943. No abstract available.

43. [Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.](#)

Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G.

World J Gastroenterol. 2006 Jul 21;12(27):4420-4.

44. [Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment.](#)

Tsochatzis E, Papatheodoridis GV, Elefsiniotis I, Thanelas S, Theodossiades G, Moulakakis A, Archimandritis AJ.

Dig Liver Dis. 2007 May;39(5):490-4. Epub 2006 Jun 19.

45. [Serological profile and virological evaluation of hepatitis B and hepatitis C virus infection among HIV infected patients in Greece.](#)

Elefsiniotis S, Paparizos V, Botsi C, Pantazis KD, Katsambas A.

Cent Eur J Public Health. 2006 Mar;14(1):22-4.

46. [Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.](#)

Elefsiniotis IS, Pantazis KD, Fotos NV, Moulakakis A, Mavrogiannis C.

J Gastroenterol Hepatol. 2006 Mar;21(3):622-3.

47. [Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease.](#)

Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, Papatsibas G, Kontou-Kastellanou C, Moulakakis A.

Eur J Gastroenterol Hepatol. 2006 May;18(5):525-30.

48. [Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.](#)

Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, Touloumi G, Economou M, Vlachogiannakos J, Spandidos D, Avgerinos A, Tzourmakliotis D.

Aliment Pharmacol Ther. 2006 Mar 15;23(6):787-95.

49. [Severe thrombotic thrombocytopenic purpura \(TTP\) induced or exacerbated by the immunostimulatory herb Echinacea.](#)

Liatsos G, Elefsiniotis I, Todorova R, Moulakakis A.

Am J Hematol. 2006 Mar;81(3):224. No abstract available. Erratum in: Am J Hematol. 2006 Sep;81(9):722. George, Liatsos [corrected to Liatsos, George]; Ioannis, Elefsiniotis [corrected to Elefsiniotis, Ioannis]; Radostina, Todorova [corrected to Todorova, Radostina]; Antonios, Moulakakis

[corrected to Moulakakis, Antonios].

50. [Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece.](#)

Elefsiniotis IS, Hero B, Mariolis A, Pantazis KD, Fotos NV, Ketikoglou I, Saroglou G.

Eur J Intern Med. 2005 Nov;16(7):496-500.

51. [Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial.](#)

Psilopoulos D, Galanis P, Goulas S, Papanikolaou IS, Elefsiniotis I, Liatsos C, Sparos L, Mavrogiannis C.

Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1111-7.

52. [HBeAg negative serological status and low viral replication levels characterize chronic hepatitis B virus-infected women at reproductive age in Greece: a one-year prospective single center study.](#)

Elefsiniotis IS, Glynou I, Magaziotou I, Pantazis KD, Fotos NV, Brokalaki H, Kada H, Saroglou G.

World J Gastroenterol. 2005 Aug 21;11(31):4879-82.

53. [Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine.](#)

Elefsiniotis IS, Moulakakis A, Pantazis KD, Glynou I, Ketikoglou I, Vezali E, Kada H, Tsianos E.

World J Gastroenterol. 2005 Apr 7;11(13):1922-8.

54. [Clinical outcome of long-term lamivudine treated chronic HBV infected and HIV/HBV coinfected patients.](#)

Elefsiniotis IS, Paparizos V, Dourakis SP, Mpotsi C, Pantazis KD, Katsambas N.

J Clin Virol. 2005 May;33(1):80-2. No abstract available.

55. [Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B.](#)

Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A.

Eur J Dermatol. 2005 Mar-Apr;15(2):107-9.

56. [Prevalence of chronic HBV infection among 13,581 women at reproductive age in Greece. A prospective single center study.](#)

Elefsiniotis IS, Glynou I, Pantazis KD, Fotos NV, Magaziotou I, Kada H.

J Clin Virol. 2005 Feb;32(2):179-80. No abstract available.

57. [Virological response in post-partum treated chronic hepatitis C women with pegylated interferon-alpha plus ribavirin. A case-control study.](#)

Elefsiniotis IS, Pantazis KD, Magaziotou I, Bogris P, Mavrogiannis C.

J Clin Virol. 2004 Dec;31(4):314-5. No abstract available.

58. [Diabetes mellitus responsive to corticosteroids in autoimmune pancreatitis.](#)

Ketikoglou IG, Elefsiniotis IS, Vezali EV, Moulakakis AM.

J Clin Gastroenterol. 2004 Nov-Dec;38(10):910. No abstract available.

59. [Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.](#)

Elefsiniotis IS, Pantazis KD, Ilias A, Pallis L, Mariolis A, Glynou I, Kada H, Moulakakis A.

Eur J Gastroenterol Hepatol. 2004 Jun;16(6):593-8

60. [Serum beta2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: relationship with virological breakthrough.](#)

Elefsiniotis IS, Scarmeas N, Glynou I, Pantazis KD, Kada H, Mavrogiannis C.

Can J Gastroenterol. 2004 May;18(5):307-13.

61. [Long-term follow-up of HIV/HBV coinfected patients from a Greek center.](#)

Elefsiniotis IS, Mpotsi C, Paparizos V, Pantazis KD.

J Clin Virol. 2004 Jul;30(3):280-1. No abstract available.

62. [Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.](#)

Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A.

Am J Gastroenterol. 2004 Jan;99(1):57-63.

63. [Plasma pituitary adenylate cyclase activating polypeptide \(PACAP\) levels in chronic hepatitis B patients under lamivudine treatment.](#)

Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C.

Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1209-16.

64. [Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis.](#)

Elefsiniotis IS, Diamantis ID, Dourakis SP, Kafiri G, Pantazis K, Mavrogiannis C.

Eur J Gastroenterol Hepatol. 2003 Jul;15(7):721-6.

65. [Ulcerative colitis associated with interferon treatment for chronic hepatitis C.](#)

Mavrogiannis C, Papanikolaou IS, Elefsiniotis IS, Psilopoulos DI, Karameris A, Karvountzis G.

J Hepatol. 2001 Jun;34(6):964-5. No abstract available.

NAME/SURENAME USING LATIN CHARACTERS. SAME WITH THOSE USED IN YOUR INTERNATIONAL SCIENTIFIC PUBLICATIONS

1.Elefsiniotis Ioannis
2.Elefsiniotis IS
3.Elefsiniotis J

[PubMed](#)



MEMBERS OF SCIENTIFIC ASSOCIATIONS

1.European Association for the Study of the Liver (EASL)
2.European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
3.Hellenic Society of Gastroenterology
4.Hellenic Association for the Study of the Liver etc